Results 1 to 10 of about 24,846 (173)

Durlobactam, a New Diazabicyclooctane β-Lactamase Inhibitor for the Treatment of Acinetobacter Infections in Combination With Sulbactam

Frontiers in Microbiology, 2021
Durlobactam is a new member of the diazabicyclooctane class of β-lactamase inhibitors with broad spectrum activity against Ambler class A, C, and D serine β-lactamases.
Adam B Shapiro, Samir H Moussa, Alita A Miller   +2 more
exaly   +3 more sources

Contribution of Acinetobacter-derived cephalosporinase-30 to sulbactam resistance in Acinetobacter baumannii

Frontiers in Microbiology, 2015
The sulbactam resistance rate in Acinetobacter baumannii has increased worldwide. Previous reports have shown that the β-lactamase blaTEM-1 confers resistance to sulbactam in A. baumannii.
Shu-Chen Kuo, Yi-Tzu Lee
exaly   +3 more sources

The combination effect of meropenem/sulbactam/polymyxin-B on the pharmacodynamic parameters for mutant selection windows against carbapenem-resistant Acinetobacter baumannii

Frontiers in Microbiology, 2022
The objective of this study was to evaluate whether combinations of sulbactam, meropenem, and polymyxin-B could reduce or close the gap of mutant selection window (MSW) of individual antibiotics against Acinetobacter baumannii harboring OXA-23.
Jiayuan Zhang, Shuo Diao, Yanfei Liu, Hongxiang Wang, Yuwei Liu, Shixing Zhu, Kun Feng, Xiaoqian Tang, Charles Oo, Peijuan Zhu, Zhihua Lv, Zhihua Lv, Mingming Yu, Mingming Yu, Sherwin K. B. Sy, Yuanqi Zhu   +15 more
doaj   +1 more source

Pulmonary Pharmacokinetic and Pharmacodynamic Evaluation of Ampicillin/Sulbactam Regimens for Pneumonia Caused by Various Bacteria, including Acinetobacter baumannii

Antibiotics, 2023
This study aimed to assess the dosing regimens of ampicillin/sulbactam for pneumonia based on pulmonary pharmacokinetic (PK)/pharmacodynamic (PD) target attainment.
Tetsushu Onita, Kazuro Ikawa, Noriyuki Ishihara, Hiroki Tamaki, Takahisa Yano, Kohji Naora, Norifumi Morikawa   +6 more
doaj   +1 more source

A New Twist: The Combination of Sulbactam/Avibactam Enhances Sulbactam Activity against Carbapenem-Resistant Acinetobacter baumannii (CRAB) Isolates

Antibiotics, 2021
An increasing number of untreatable infections are recorded every year. Many studies have focused their efforts on developing new β-lactamase inhibitors to treat multi-drug resistant (MDR) isolates. In the present study, sulbactam/avibactam and sulbactam/
Fernando Pasteran, Jose Cedano, Michelle Baez, Ezequiel Albornoz, Melina Rapoport, Jose Osteria, Sabrina Montaña, Casin Le, Grace Ra, Robert A. Bonomo, Marcelo E. Tolmasky, Mark Adams, Alejandra Corso, Maria Soledad Ramirez   +13 more
doaj   +1 more source

Zidebactam restores sulbactam susceptibility against carbapenem-resistant Acinetobacter baumannii isolates

Frontiers in Cellular and Infection Microbiology, 2022
Carbapenems are commonly used to treat infections caused by multidrug-resistant (MDR) bacteria. Unfortunately, carbapenem resistance is increasingly reported in many gram-negative bacteria, especially Acinetobacter baumannii.
Jose Cedano, Michelle Baez, Fernando Pasteran, Sabrina Daiana Montaña, Grace Ra, Venjaminne Fua, Alejandra Corso, Marcelo E. Tolmasky, Robert A. Bonomo, Robert A. Bonomo, Robert A. Bonomo, María Soledad Ramírez   +11 more
doaj   +1 more source

High-dose Sulbactam Treatment for Ventilator-Associated Pneumonia Caused by Carbapenem-Resistant [PDF]

Korean Journal of Critical Care Medicine, 2016
Background Several antibiotics can be used to treat ventilator-associated pneumonia caused by carbapenem-resistant A. baumannii (CRAB-VAP) including high-dose sulbactam. However, the effectiveness of high-dose sulbactam therapy is not well known.
In Beom Jeong, Moon Jun Na, Ji Woong Son, Do Yeon Jo, Sun Jung Kwon   +4 more
doaj   +1 more source

Alteration of adeS Contributes to Tigecycline Resistance and Collateral Sensitivity to Sulbactam in Acinetobacter baumannii

Microbiology Spectrum, 2023
The treatment of extensively drug-resistant (XDR) A. baumannii has emerged as a major problem. Tigecycline (TGC) and sulbactam (SUL) are both effective antibiotics against XDR A. baumannii.
Yunxing Yang, Xiaochen Liu, Danyan Zhou, Jintao He, Qiong Chen, Qingye Xu, Shenghai Wu, Weiying Zhang, Yue Yao, Ying Fu, Xiaoting Hua, Yunsong Yu, Xianjun Wang   +12 more
doaj   +1 more source

A green approach to the analysis of co-administered ampicillin/sulbactam and paracetamol in human urine

Acta Pharmaceutica, 2022
The novelty of this work is the simultaneous analysis of sulbactam (SUL), ampicillin (AMP), and paracetamol (PARA) in human urine samples, using the environmentally benign RP-HPLC method.
SELIM BASMA M., ABDELSALAM RANDA A., EL-GINDY ALAA, EID BASMA G., NEAMATALLAH THIKRYAT, KHAYYAT AHDAB N., HADAD GHADA M., ELKHOUDARY MAHMOUD M.   +7 more
doaj   +1 more source

Effects of amikacin, polymyxin-B, and sulbactam combination on the pharmacodynamic indices of mutant selection against multi-drug resistant Acinetobacter baumannii

Frontiers in Microbiology, 2022
Amikacin and polymyxins as monotherapies are ineffective against multidrug-resistant Acinetobacter baumannii at the clinical dose. When polymyxins, aminoglycosides, and sulbactam are co-administered, the combinations exhibit in vitro synergistic ...
Shixing Zhu, Chu Song, Jiayuan Zhang, Shuo Diao, Tobias M. Heinrichs, Frederico S. Martins, Zhihua Lv, Zhihua Lv, Yuanqi Zhu, Mingming Yu, Mingming Yu, Sherwin K. B. Sy   +11 more
doaj   +1 more source